Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Alpha Cognition (NASDAQ:ACOG) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock.

Separately, Raymond James raised shares of Alpha Cognition to a “moderate buy” rating in a report on Tuesday, March 25th.

Alpha Cognition Stock Down 8.5 %

Shares of ACOG stock opened at $5.06 on Monday. The stock has a market capitalization of $81.06 million, a P/E ratio of -1.98 and a beta of 2.50. Alpha Cognition has a 52-week low of $4.66 and a 52-week high of $7.00. The stock has a fifty day simple moving average of $5.83.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings results on Wednesday, April 2nd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

Institutional Trading of Alpha Cognition

Hedge funds and other institutional investors have recently bought and sold shares of the company. National Bank of Canada FI bought a new stake in shares of Alpha Cognition in the 4th quarter worth approximately $69,000. Manatuck Hill Partners LLC bought a new stake in Alpha Cognition in the fourth quarter worth $395,000. Tudor Investment Corp ET AL purchased a new stake in Alpha Cognition during the fourth quarter valued at about $412,000. MYDA Advisors LLC bought a new position in shares of Alpha Cognition during the fourth quarter valued at about $589,000. Finally, Bleichroeder LP bought a new position in shares of Alpha Cognition during the fourth quarter valued at about $1,024,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.